Scientists Identify Two Genes That Could Transform Heart Attack Diagnosis

When a heart attack strikes, every minute of delay in diagnosis translates directly into lost heart muscle, yet the clinical tools physicians rely on today—troponin blood tests, electrocardiograms, coronary angiography—share a fundamental blind spot. They can only confirm what has already gone wrong: that heart cells have died. A new study published in the journal Molecular Genetics & Genomic Medicine now points to something different—a molecular early warning system built from the genes that heart tissue switches on in the chaotic first hours of oxygen starvation. By combining large-scale bioinformatics with animal experimentation, researchers have identified two genes, PLAUR and IL1B, as central hub genes governing the hypoxia–ischemia–inflammation cascade that unfolds immediately after a coronary artery is blocked, and their work suggests these genes could add a genuinely new dimension to how acute myocardial infarction is detected and risk-stratified.

The research team, led by Longsheng Zhang and Ning Liang of Guangxi Medical University, began with a question that has haunted cardiology for decades: what actually happens, at the level of gene expression, in the earliest phase of a heart attack, before irreversible necrosis sets in? Myocardial infarction remains one of the leading causes of cardiovascular death worldwide, and its core mechanism—a sudden coronary occlusion depriving heart muscle of oxygen—triggers cell death, adverse cardiac remodeling, and often irreversible heart failure. Although interventions such as percutaneous coronary intervention and anticoagulation have dramatically improved short-term survival, long-term complications including ischemia–reperfusion injury and chronic heart failure continue to erode patients’ quality of life. Understanding the molecular regulatory machinery that decides whether oxygen-starved cardiomyocytes survive or die is therefore considered crucial for unlocking new therapeutic targets.

To attack the problem systematically, the researchers mined three publicly available gene expression datasets—GSE48060, GSE97320, and GSE66360—from the Gene Expression Omnibus database, all generated on the Affymetrix Human Genome U133 Plus 2.0 platform using peripheral whole blood samples from acute myocardial infarction patients and healthy individuals. After merging the training datasets and eliminating batch effects using the ComBat method, they applied differential expression analysis with stringent statistical thresholds, uncovering 633 differentially expressed genes between heart attack patients and controls—464 upregulated and 169 downregulated. The team then cross-referenced this list against a curated repository of 308 hypoxia- and ischemia-related genes assembled from the GeneCards database and prior literature, narrowing the field to 21 genes that sit squarely at the intersection of heart attack biology and oxygen deprivation.

The analytical machinery that followed was equally rigorous. The researchers constructed a protein–protein interaction network using the STRING database and visualized it in Cytoscape, retaining only high-confidence interactions. A tightly connected functional module of eight genes—PTGS2, CXCR4, PLAUR, MMP9, CXCL8, PTEN, IL1B, and TLR4—emerged from module detection analysis. Meanwhile, six independent topological algorithms within the cytoHubba plugin, including maximal clique centrality, degree, closeness, radiality, and eigenvector-based measures, converged on largely the same set of hub candidates. In parallel, the team deployed a random forest machine learning model with 500 decision trees, ranking genes by their contribution to classification accuracy. The decisive moment came when the outputs of the network analysis and the machine learning model were overlapped: only two genes, PLAUR and IL1B, survived the intersection, marking them as the central molecular players in the hypoxic-inflammatory response to myocardial infarction.

Functional enrichment analysis added biological context to the shortlist. The 21 hypoxia-ischemia-related genes were significantly enriched in inflammatory signaling cascades, including the IL-17 signaling axis and the NF-κB pathway, along with lipid metabolism and atherosclerosis-related routes, cytokine–cytokine receptor interaction networks, and responses to bacterial-derived molecules such as lipopolysaccharide. Molecular function annotations highlighted urokinase plasminogen activator receptor activity—encoded by PLAUR—alongside AMP binding and erythropoietin receptor function. The picture that emerges is coherent: in the hours after coronary occlusion, the body mounts an intense inflammatory and fibrinolytic response, and the genes identified sit at the control nodes of that response rather than at its periphery.

The diagnostic credentials of the two hub genes were then tested against the independent GSE66360 validation cohort, a dataset the algorithm had never seen during training. Both PLAUR and IL1B were markedly elevated in acute myocardial infarction patients compared with healthy controls, with statistical significance at the p < 0.0001 level. Receiver operating characteristic analysis quantified their discriminatory power: PLAUR achieved an area under the curve of 0.78, and IL1B scored 0.75—both comfortably above the conventional threshold of 0.7 for a clinically meaningful biomarker. More impressively, when the two genes were combined in a logistic regression model, calibration curves showed that predicted probabilities closely tracked actual outcomes, and decision curve analysis demonstrated that the two-gene model delivered greater net clinical benefit across all risk thresholds than either a treat-all or treat-none strategy.

Critical to the study’s credibility was its move beyond computer screens into living tissue. The team established an acute myocardial infarction model in eight-week-old male C57BL/6J mice by ligating the left anterior descending coronary artery under continuous ECG monitoring and mechanical ventilation, with sham-operated animals undergoing identical surgery without ligation. G*Power calculations determined that eight animals per group constituted the minimum sample size, with ten assigned to accommodate surgical attrition. Twenty-four hours after the induction of ischemia, hematoxylin and eosin staining revealed the expected histological signature of infarction—extensive myocardial necrosis, cellular degeneration, hypertrophy, and disorganized muscle fiber architecture—in the model group, while sham tissues retained normal morphology. Quantitative PCR then delivered the study’s most important experimental confirmation: mRNA levels of both PLAUR and IL1B were significantly upregulated in the ischemic heart tissue itself, demonstrating that the transcriptomic signals detected in human blood genuinely reflect activity within the injured myocardium rather than mere systemic noise.

The mechanistic stories behind each gene are compelling. PLAUR, a key molecule of the fibrinolytic system, appears to worsen hypoxic myocardial injury through two parallel routes: it activates plasminogen to generate plasmin, and excessive fibrinolysis disrupts the structural integrity of the myocardial extracellular matrix, promoting infarct expansion; independently, it activates the PI3K-Akt and NF-κB signaling pathways, driving secretion of inflammatory mediators such as IL-6 and TNF-α and amplifying the post-ischemic inflammatory storm. IL-1β, meanwhile, is directly controlled by HIF-1α, the master hypoxia sensor. When oxygen levels plummet, HIF-1α accumulates and binds the hypoxia response element in the IL-1β promoter, ramping up transcription of this classic pro-inflammatory cytokine. Secreted IL-1β then binds receptors on cardiomyocytes, activating the MAPK/JNK pathway—a cascade that induces cardiomyocyte apoptosis, suppresses vascular endothelial proliferation, and impedes new blood vessel formation in the infarct zone, deepening the ischemic injury.

The clinical implications are what make this study genuinely exciting. Elevated troponin, the current gold standard, only indicates myocardial injury that has already become irreversible, and it cannot predict progressive inflammatory deterioration before overt necrosis occurs. In contrast, transcriptional upregulation of PLAUR and IL1B is triggered rapidly after coronary occlusion. Quantifying peripheral blood transcript levels of these genes could identify, earlier than any existing test, which patients are prone to severe inflammatory decompensation—allowing emergency departments to escalate monitoring, initiate personalized anti-inflammatory regimens, and apply enhanced cardioprotective strategies to high-risk subgroups. The researchers argue that these transcriptional biomarkers will not replace troponin assays, electrocardiography, or angiography, but will add an additional molecular phenotype layer to emergency risk triage. They also point to actionable therapeutic horizons: anti-IL1B monoclonal antibodies have already shown cardioprotective effects and reduced post-infarction ventricular remodeling in clinical trials of inflammatory heart disease, while the urokinase-type plasminogen activator receptor encoded by PLAUR is emerging as a promising modulator of cardiac reparative cell therapy, potentially pharmacologically targetable to boost the regenerative capacity of cardiac progenitor cells.

The authors are candid about their limitations. The human transcriptomic data came from peripheral whole blood rather than myocardial biopsies, meaning circulating transcripts reflect systemic inflammation—although the mouse qPCR results confirmed genuine cardiac upregulation. Only mRNA was quantified in animal tissue; protein expression, subcellular localization, and gain- or loss-of-function experiments remain to be performed, so causal roles cannot yet be definitively claimed. And the moderate AUC values make clear that standalone gene tests cannot replace established diagnostics. The team’s stated next step is to build a multivariable predictive model incorporating age, hypertension, diabetes, peak troponin, TIMI flow grade, and PLAUR/IL1B expression values—borrowing from machine learning frameworks already validated for perioperative myocardial injury and acute pulmonary embolism—followed by rigorous prospective validation across diverse patient populations. If that program succeeds, the humble pair of genes identified in this study could become the first molecular sentinels of a heart attack’s inflammatory future, flagged in a blood sample long before the damage becomes permanent.

Subject of Research: Identification of hypoxia- and ischemia-related hub genes in myocardial infarction through bioinformatics analysis and experimental validation

Article Title: Bioinformatics Analysis and Experimental Validation of Key Genes Associated With Hypoxia and Ischemia in Myocardial Infarction

Article References: Zhang, L., & Liang, N. (2026). Bioinformatics Analysis and Experimental Validation of Key Genes Associated With Hypoxia and Ischemia in Myocardial Infarction. Molecular Genetics &amp; Genomic Medicine, 14(9), Article e70284. https://doi.org/10.1002/mgg3.70284

Image Credits: AI Generated

DOI: 10.1002/mgg3.70284

Keywords: myocardial infarction, hypoxia, ischemia, PLAUR, IL1B, biomarkers, bioinformatics, random forest, heart attack diagnosis, inflammation, cardiology, qPCR